In light of our observation that administration of fetuin-A markedly reduced circulating levels of HMGB1, but not TNF-α (data not shown), we propose that fetuin-A confers protection against lethal endotoxemia and sepsis partly by inhibiting late mediators of these diseases. Here, HMGB1 is linked to serum lipopolysaccharide activity.